Evidence map›Paper›PMID 33779548›Full record

ArticleeLife2021

Saliva TwoStep for rapid detection of asymptomatic SARS-CoV-2 carriers.

Qing Yang, Nicholas R Meyerson, Stephen K Clark, Camille L Paige, Will T Fattor, Alison R Gilchrist, Arturo Barbachano-Guerrero, Benjamin G Healy, Emma R Worden-Sapper, Sharon S Wu and 15 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. A Colorimetric LAMP Assay forFoods (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 2 institutions in 1 country.

Qing Yang *BioFrontiers Institute, University of Colorado Boulder, Boulder, United States.ORCID 0000-0001-9053-3158
Nicholas R Meyerson *BioFrontiers Institute, University of Colorado Boulder, Boulder, United States.
Stephen K ClarkBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.
Camille L PaigeBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.ORCID 0000-0002-7620-3977
Will T FattorBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.ORCID 0000-0002-6477-3139
Alison R GilchristBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.
Arturo Barbachano-GuerreroBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.ORCID 0000-0001-7483-839X
Benjamin G HealyDepartment of Mechanical Engineering, University of Colorado Boulder, Boulder, United States.
Emma R Worden-SapperBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.ORCID 0000-0002-5823-3566
Sharon S WuBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.
Denise MuhlradDepartment of Biochemistry, University of Colorado Boulder, Boulder, United States.
Carolyn J DeckerDepartment of Biochemistry, University of Colorado Boulder, Boulder, United States.
Tassa K SaldiBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.
Erika LasdaBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.
Patrick GonzalesBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.
Morgan R FinkBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.ORCID 0000-0002-0567-3234
Kimngan L TatBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.
Cole R HagerBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.
Jack C DavisDepartment of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, United States.
Christopher D OzeroffBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.
Gloria R BrissonWardenburg Health Center, University of Colorado Boulder, Boulder, United States.
Matthew B McQueenDepartment of Integrative Physiology, University of Colorado Boulder, Boulder, United States.
Leslie A LeinwandBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.ORCID 0000-0003-1470-4810
Roy ParkerBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.ORCID 0000-0002-8412-4152
Sara L SawyerBioFrontiers Institute, University of Colorado Boulder, Boulder, United States.ORCID 0000-0002-6965-1085
University of Colorado Boulder · USHoward Hughes Medical Institute · US

Funding

MYOSIN GENE DIVERSITY AND FUNCTIONR01GM029090 · NIGMS · YESHIVA UNIVERSITY · PI Leslie Anne Leinwand · 1985 to 2026
$12.3M
Hunting the HIV-1 UnicornDP1DA046108 · NIDA · UNIVERSITY OF COLORADO · PI SAWYER, SARA · 2018 to 2022
$4.5M
Host genetic barriers to virus spilloverR01AI137011 · NIAID · UNIVERSITY OF COLORADO · PI SAWYER, SARA · 2018 to 2022
$2.1M
Burroughs Wellcome Fund PATHBurroughs Wellcome Fund PDEPNIAID NIH HHS R01 AI137011NIDA NIH HHS DP1 DA046108NIGMS NIH HHS R01 GM029090NIH HHS DP1-DA-046108
6 · The paper itself

Abstract

Here, we develop a simple molecular test for SARS-CoV-2 in saliva based on reverse transcription loop-mediated isothermal amplification. The test has two steps: (1) heat saliva with a stabilization solution and (2) detect virus by incubating with a primer/enzyme mix. After incubation, saliva samples containing the SARS-CoV-2 genome turn bright yellow. Because this test is pH dependent, it can react falsely to some naturally acidic saliva samples. We report unique saliva stabilization protocols that rendered 295 healthy saliva samples compatible with the test, producing zero false positives. We also evaluated the test on 278 saliva samples from individuals who were infected with SARS-CoV-2 but had no symptoms at the time of saliva collection, and from 54 matched pairs of saliva and anterior nasal samples from infected individuals. The Saliva TwoStep test described herein identified infections with 94% sensitivity and >99% specificity in individuals with sub-clinical (asymptomatic or pre-symptomatic) infections.

Indexed as

Carrier StateCOVID-19COVID-19 TestingHumansMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesRNA, ViralSalivaSARS-CoV-2Sensitivity and SpecificitySpecimen HandlingRNA, Viralinfectious diseasemicrobiologySARS-CoV-2testinguniversityvirus

Identifiers

PMID33779548
PMCPMC8057811
OpenAlexW3151098594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.